prikaz prve stranice dokumenta Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection
  Preuzmi
PDF 1.15 MB
Znanstveni rad - Izvorni znanstveni rad
Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection
Journal of Clinical Medicine, 11 (2022), 22; 6695. https://doi.org/10.3390/jcm11226695
Krpina, Kristina; Mavrinac, Martina; Samaržija, Miroslav; Tolić, Ena; Darapi, Dora; Batičić, Lara

Citirajte ovaj rad

Krpina, K., Mavrinac, M., Samaržija, M., Tolić, E., Darapi, D. i Batičić, L. (2022). Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection. Journal of Clinical Medicine, 11. (22). doi: 10.3390/jcm11226695

Krpina, Kristina, et al. "Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection." Journal of Clinical Medicine, vol. 11, br. 22, 2022. https://doi.org/10.3390/jcm11226695

Krpina, Kristina, Martina Mavrinac, Miroslav Samaržija, Ena Tolić, Dora Darapi i Lara Batičić. "Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection." Journal of Clinical Medicine 11, br. 22 (2022). https://doi.org/10.3390/jcm11226695

Krpina, K., et al. (2022) 'Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection', Journal of Clinical Medicine, 11(22). doi: 10.3390/jcm11226695

Krpina K, Mavrinac M, Samaržija M, Tolić E, Darapi D, Batičić L. Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection. Journal of Clinical Medicine [Internet]. 2022. [pristupljeno 22.10.2024.];11(22). doi: 10.3390/jcm11226695

K. Krpina, M. Mavrinac, M. Samaržija, E. Tolić, D. Darapi i L. Batičić, "Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection", Journal of Clinical Medicine, vol. 11, br. 22, 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:583604. [Citirano: 22.10.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:583604
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection
AutorKristina Krpina
AutorMartina Mavrinac
AutorMiroslav Samaržija
AutorEna Tolić
AutorDora Darapi
AutorLara Batičić
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za medicinsku informatiku)
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za medicinsku kemiju, biokemiju i kliničku kemiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Intenzivna medicina
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Infektologija
Sažetak (engleski)
Introduction: Lung cancer is one of the most diagnosed malignancies with increasing incidence worldwide. Immunotherapy is the main oncological treatment for advanced non-small cell lung cancer (NSCLC), for which the discovery of new efficient biomarkers is crucial. Scientific evidence points to the importance of the Lung Immune Prognostic Index (LIPI), but its predictive significance is unclear. Aim: The aim of this study was to investigate the clinical significance and predictive role of LIPI in patients with advanced NSCLC and PD-L1 mutation who are eligible for immunotherapy in combination with chemotherapy. In addition, to our knowledge, this is the first time that the association between COVID-19 infection and the course and outcome of oncologic treatment of NSCLC has been investigated. Patients and Methods: Patients were divided into four study groups according to strictly defined clinical parameters, therapeutic approach, and COVID-19 infection. LIPI was determined and its predictive power was evaluated in all studied groups, as well as overall survival (OS), progression-free survival (PFS), and disease control rate (DCR). Results: This study confirmed the understudied and uncertain predictive power and clinical relevance of LIPI as a biomarker in patients with advanced NSCLC. Patients infected with COVID-19 had a higher survival rate than uninfected patients despite the therapeutic approach, which may be attributed to their hospitalization and intensive medical management during the pandemic. Conclusions: Findings obtained in this study may help to determine treatment options according to the clinical condition of the patient by using LIPI values as a non-invasive, readily available and economically acceptable predictive biomarker in lung oncology.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaJournal of Clinical Medicine
Brojčani podacivol. 11, br. 22, 6695
p-ISSN2077-0383
DOIhttps://doi.org/10.3390/jcm11226695
URN:NBNurn:nbn:hr:184:583604
Datum objave publikacije2022
URL dokumentahttp://bib.irb.hr/1233975
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2022-11-30 14:23:00